Angola
Tuberculosis profile
| High HIV burden |
Population  2013 21 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.9 (3.5–9.9) 32 (16–46)
Mortality (HIV+TB only) 1.6 (1.1–2.1) 7.3 (5.3–9.7)
Prevalence  (includes HIV+TB) 91 (45–150) 423 (209–711)
Incidence  (includes HIV+TB) 69 (61–76) 320 (286–353)
Incidence (HIV+TB only) 7.5 (6.7–8.3) 35 (31–39)
Case detection, all forms (%) 85 (77–95)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
920 (48–2 600) 1 500 (8–3 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 21 661   5 353
Pulmonary, clinically diagnosed 26 758   0
Extrapulmonary 4 835   0
       
Total new and relapse 58 607    
Previously treated, excluding relapses 2 200    
Total cases notified 60 807    
Among 21 661 new cases:
1 112 (5%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 232 (3%) 232
Laboratory-confirmed RR-/MDR-TB cases     232
Patients started on MDR-TB treatment     116
TB/HIV 2013 Number (%)
TB patients with known HIV status 24 445 (40)
HIV-positive TB patients 2 674 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 674 (100)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 246  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 45
Previously treated cases, excluding relapse, registered in 2012 20
HIV-positive TB cases, all types, registered in 2012 0
RR-/MDR-TB cases started on second-line treatment in 2011 0
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 18
% Funded domestically 63%
% Funded internationally 13%
% Unfunded 24%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-24 Data: www.who.int/tb/data